Choroidal Thickness in Glaucoma Patients and Healthy Controls

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01293474

Enrollment

200

Registered

2011-02-10

Start date

2011-02-28

Completion date

2015-12-31

Last updated

2015-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma Patients and Healthy Controls

Brief summary

With the new software tool (EDI, enhanced depth imaging) of the Spectralis® spectral-domain optical coherence tomography (SD-OCT) it is possible to visualize and measure the choroidal thickness. In glaucoma a vascular component is known. Therefore a difference of choroidal thickness in glaucoma patients and healthy controls is proposed. * Trial with medical device

Interventions

DEVICESpectralis® SD-OCT, Heidelberg Engineering GmbH, H

Measurement of the choroidal thickness with Spectralis® SD-OCT

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

for both groups (glaucoma study group and control group): men and women of at least 50 years of age for the glaucoma study group: diagnosis of primary open angle glaucoma (POAG)

Exclusion criteria

for both groups (glaucoma study group and control group): * less then 50 years of age * any pathology of the central retina * any optic nerve disorder other then glaucoma * retinal vascular disorder for the glaucoma study group: other glaucoma diagnosis then primary open angle glaucoma for the control group: any diagnosis of glaucoma

Design outcomes

Primary

Measure	Time frame
COV	t0

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026